Company intelligence / Profile preview

Luminesce Alliance

Westmead, NSW, Australia

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Luminesce Alliance has successfully integrated genomic sequencing into the clinical care of children with high-risk cancers and rare diseases. Its PRISM clinical trial has demonstrated that precision medicine can identify actionable therapeutic targets for over 70% of pediatric patients with refractory or high-risk cancer, leading to improved outcomes in clinical practice.

Therapeutic areas: OncologyRare DiseasesMetabolic Disorders
Modalities: Gene therapyCell therapyCAR-T cell therapySmall moleculeMonoclonal antibodyPrecision medicineGenomics
Industry: Academic Hospital/University/Research

Partnerships

Sydney Children's Hospitals NetworkChildren's Medical Research InstituteChildren's Cancer InstituteUniversity of SydneyUNSW SydneyNSW Government

Beyond the preview

Go deeper on Luminesce Alliance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luminesce Alliance.

Explore the full profile